~ Buy the INGREZZA (valbenazine tosylate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR INGREZZA

All Clinical Trials for Ingrezza

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03325010 ↗	Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome	Completed	Neurocrine Biosciences	Phase 2	2017-10-05	This is a Phase 2b, randomized, double-blind, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of NBI-98854 titrated to the subject's optimal dose administered once daily (qd) for a total of 12 weeks of treatment in pediatric subjects with TS.
NCT03444038 ↗	Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome	Completed	Neurocrine Biosciences	Phase 2	2018-02-08	This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.
NCT03530293 ↗	Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome	Terminated	Neurocrine Biosciences	Phase 2	2018-04-16	This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.
NCT03732534 ↗	Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome	Terminated	Neurocrine Biosciences	Phase 2	2018-10-17	This is an open-label, rollover study to collect long-term safety, tolerability, and investigator- and participant-reported pharmacodynamic (PD) data after chronic administration of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide open-label access to NBI-98854 for the treatment of TS for pediatric participants who have taken part in a Phase 2 NBI-98854 study.
NCT05157100 ↗	Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia	Enrolling by invitation	The Orthopedic Foundation	Phase 4	2021-10-19	STUDY OF INGREZZA (VALBENAZINE) FOR THE TREATMENT OF CERVICAL DYSTONIA

Clinical Trial Conditions for Ingrezza

Condition Name

Condition Name for Ingrezza
Intervention	Trials
Tourette Syndrome	4
Developmental Disabilities	1
Intellectual Disability	1
Tardive Dyskinesia	1

Condition MeSH

Condition MeSH for Ingrezza
Intervention	Trials
Tourette Syndrome	4
Syndrome	4
Trichotillomania	1
Torticollis	1

Clinical Trial Locations for Ingrezza

Trials by Country

Trials by Country for Ingrezza
Location	Trials
United States	66
Puerto Rico	4

Trials by US State

Trials by US State for Ingrezza
Location	Trials
Ohio	4
Texas	4
Nebraska	4
Illinois	4
Florida	4

Clinical Trial Progress for Ingrezza

Clinical Trial Phase

Clinical Trial Phase for Ingrezza
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	5

Clinical Trial Status

Clinical Trial Status for Ingrezza
Clinical Trial Phase	Trials
Not yet recruiting	2
Terminated	2
Completed	2

Clinical Trial Sponsors for Ingrezza

Sponsor Name

Sponsor Name for Ingrezza
Sponsor	Trials
Neurocrine Biosciences	6
The Orthopedic Foundation	1
Michael Bloch	1

Sponsor Type

Sponsor Type for Ingrezza
Sponsor	Trials
Industry	6
Other	3